Emboldened by Research, Roche Said It Will Shoot for Molecular Dx, Tx for Osteoporosis | GenomeWeb

Encouraged by research linking a gene with bone mass density, Roche Palo Alto plans to develop what the Swiss company hopes will become the first molecular diagnostic for osteoporosis risk, SNPtech Pharmacogenomics Reporter has learned.

The company said it also hopes to develop a therapeutic that would target the product of that gene, Alox15, and help delay or even reverse the onset of osteoporosis — a disease that costs US health-care facilities $17 billion a year to treat, according to the National Osteoporosis Foundation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.